Myasthenia Gravis - Pipeline Review, H2 2016; New Report Launched
Myasthenia Gravis pipeline therapeutics constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes. Publisher's latest report Myasthenia Gravis – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
View full press release